Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma

• Firas Baidoun,
• Zahi Merjaneh,
• Fatma Abd-Elshahed Abd-Elhay,
• Mohamed Gomaa Kamel

Affiliations

Firas Baidoun

Department of Hospital Medicine, Cleveland Clinic Foundation, Cleveland, OH 44145, United States

Zahi Merjaneh

Department of Hospital Medicine, Cleveland Clinic Foundation, Cleveland, OH 44145, United States

Fatma Abd-Elshahed Abd-Elhay

Faculty of Medicine, Minia University, Minia, Egypt

Mohamed Gomaa Kamel

Faculty of Medicine, Minia University, Minia, Egypt; Corresponding author.